Bioprinting is ready to create tissue products with high commercial and therapeutic value, but engineered organs are still to come. Early investors are jumping in while Big Pharma moves bioprinting companies in house, new players enter the field, and stakeholders are collaborating at entry level. Government agencies are committing extensive resources to the technology, with regulators preparing to handle bioprinted products.
In this in-depth article in BioProcess International, authors from Charles River Associates talk about the need to negotiate key development hurdles to make this technology viable for the biopharmaceutical industry.